Member area login

You don't have or don't remember the password!
Click Here

Editor-in-chief
Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

EIC Assistant
Francesco Busardò

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada

Publisher
Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Chiara Riva
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282
email: biochimica.clinica@sibioc.it

--------------------

ISSN print: 0393 – 0564
ISSN digital: 0392- 7091

BC: Articoli scritti da R. Moratti

Identificazione di danno renale reversibile e di precoce risposta alla chemioterapia in pazienti con amiloidosi AL
Identification of reversible renal damage and early response to chemotherapy in AL amyloidosis
P. Milani \| G. Palladini \| U. Hegenbart \| C. Kimmich \| A. Foli \| A.D. Ho \| M. Vidus Rosin \| R. Albertini \| R. Moratti \| S. Schönland \| G. Merlini \|
<p>The kidney is involved in 70% of patients with immunoglobulin light-chain (AL) amyloidosis, but little is known on progression or reversibility of renal involvement. Furthermore, criteria for renal response have never been validated. We designed a staging system for renal damage and identified criteria for renal response and progression in a population of 732 newly diagnosed patients with AL amyloidosis. The population was composed of 461 patients from Pavia (testing cohort) and 271 subjects from Heidelberg (validation cohort). Baseline proteinuria >5 g/24 h and estimated glomerular filtration rate (eGFR) <50 mL/min/1.73 m<sup>2</sup> were independently associated with poorer renal survival and discriminated between 3 stages (with none, one or two markers above the cut-off) with significant different renal survival. At 6-month follow-up, a ≥25% eGFR decrease predicted poor renal survival in both cohorts and was adopted as criterion for renal progression. A decrease in proteinuria ≥30% or below the cut-off of 0.5 g/24 h in absence of renal progression were the criteria for renal response, being associated with longer renal survival in the testing and validation cohorts. These endpoints can be used as validated response criteria in renal AL amyloidosis, allowing early assessment of treatment efficacy.</p>
Biochimica Clinica ; 40(1) 21-27 Contributi scientifici - Scientific Papers